Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2072649 | 0.88 | ALDH1A1 (0.40) | MEN1KMT2ANPSR1ALDH1A1USP2 | |
| SCHEMBL15573689 | 0.84 | FKBP1A (0.41) | MEN1KMT2ANPSR1ALDH1A1USP2 | |
| SCHEMBL16768111 | 0.77 | DDB1 (0.40) | MEN1KMT2ANPSR1ALDH1A1 | |
| SCHEMBL2072822 | 0.76 | MEN1 (0.53) | MEN1KMT2ANPSR1 | |
| SCHEMBL6132960 | 0.74 | JAK2 (0.44) | ALDH1A1GAA | |
| SCHEMBL20599446 | 0.74 | ALDH1A1 (0.46) | MEN1KMT2ANPSR1ALDH1A1 | |
| SCHEMBL1256462 | 0.73 | ALDH1A1 (0.51) | MEN1KMT2ANPSR1ALDH1A1 | |
| SCHEMBL19124519 | 0.73 | MEN1 (0.44) | MEN1KMT2ANPSR1 | |
| SCHEMBL11301180 | 0.73 | CYP3A4 (0.53) | MEN1KMT2ANPSR1ALDH1A1GAA | |
| SCHEMBL8473737 | 0.72 | ALDH1A1 (0.47) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340538-B2 | Dihydropyrimidine compounds and their application in pharmaceuticals | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-05-17 | — | — | US | disclosed |
| US-9340538-B2 | Dihydropyrimidine compounds and their application in pharmaceuticals | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2016-05-17 | — | — | US | disclosed |
| US-20150152096-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-06-04 | — | — | US | disclosed |
| US-20150152096-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152096-A1 | DIHYDROPYRIMIDINE COMPOUNDS AND THEIR APPLICATION IN PHARMACEUTICALS | DPYD, SLC10A1, HPRT1 | MEN1 1746/4885KMT2A 3244/4885NPSR1 3221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.